Stocks of companies that are at the beginning of their growth cycle are eligible for investment. These companies are often characterized by the fact that their products are close to market launch or are new to the market. Particular attention is also paid to a solid financial situation.
We combine our approach and decades of industry expertise in our in-house database of more than 900 stocks. The focus is on those segments of the healthcare sector that promise above-average growth: Biotechnology, medical technology, niche and specialty areas of the pharmaceutical sector.
Our approach is to strategically accompany the selected companies in the phase of their strongest growth, because only in the long term can the companies also develop their high potential. The aim is to achieve the broadest possible diversification, with weightings based on a balance of opportunities and risks.
Successful investment in the healthcare sector requires not only intensive scrutiny and analysis, but also staying power. Only investors who think long-term and therefore strategically have the chance to participate in these high potentials.